Ocular responses to foreign corneal and tumor issue

Essen, T.H. van (2018)

Doctoral Thesis

We used the corneal immunosuppressive environment to test the possibility of inserting a Fish Scale-Derived Collagen Matrix in a corneal pocket, and the excellent results and lack of primary and secondary immune responses led to a clinical trial, which is currently underway.
The immunosuppressive environment of the eye allows the growth of malignant melanocytes which leads to the formation of uveal melanoma. The association between increased numbers of macrophages and lymphocytes in uveal melanoma and an increased development of uveal melanoma metastases suggest an influence of pro-angiogenic macrophages, The relation between loss of BAP1 expression and a very bad prognosis and the influx of leukocytes into the primary tumor, suggests that BAP1 functions as a regulator of inflammation. Further research will focus on the role of BAP1 in the regulation of inflammation in the uveal melanoma microenvironment.

• Artificial cornea
• Uveal melanoma
• Choroidea melanoma
• Keratoprosthesis
• HLA
• Immunoresponse
• Rejection
• Prognosis
• Immune response

• All authors: Essen, T.H. van
• Supervisor: Jager, M.J.; Luyten, G.P.M.
• Co-supervisor: Ghalbzouri, A. el
• Committee: Claas, F.H.J.; Lagali, N.S.; Haas, M. de; Zaal, M.J.W.; Boon, C.J.M.; Romanovska-Dixon, B.; Verdijk, R.M.
• Qualification: Doctor (dr.)
• Awarding Institution: Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University
• Date: 2018-11-14
• ISBN (print): 9789463750769
• Sponsorship: Financial support The research about the artificial cornea described in this thesis was suported by a grant from Agentschap.nl Publication of this thesis was supported by Laméris Ootech, Rockmed, Haags Kunstogen Laboratorium, Alcon NL, Croma Pharma, Bayer, Laservision Intstruments, EyeMed Vision Care, Théa Pharma, Ursapharm, Zeiss, Tramedico, Elvea Low Vision, Chiesi Pharmaceuticals, Ergra Low Vision, Stichting Blindenhulp, Landelijke Stichting Blinden en Slechtszienden, Leids Oogheelkundig OndersteuningsFonds